Lancet oncol: Clinical characteristics and risk factors for cancer patients infected with the new coronavirus in Wuhan

COVID-19 has spread around the worldCancer patients are reported to be epidemiologically sensitive to the new coronavirusThe purpose of this study is to systematically describe the clinical characteristics of coVID-19 in cancer patients and to determine clearly the risk factors for the severity of COVID-19 infection in cancer patientsThis study is a multi-center retrospective cohort study that was included in all patients aged 18 and over who have been laboratory-confirmed to be infected with any tumor of COVID-19 in a multi-center edteamy studyOn the basis of age, sex, and co-disease, the tendivity scores of the patients in the group were statistically matched (2:1) in patients with COVID-19 who were not without cancerCompared with January 13 - March 18, 2020, a total of 13,077 CASES OF COVID-19 infection were confirmed in nine hospitals in Wuhan, of which 232 were cancer patients and 519 matching non-cancer patients were recruitedThe median follow-up for cancer patients was followed for 29 days and for non-cancer patients for 27 daysCancer patients who are infected with COVID-19 tend to develop severe cases more often than non-cancer patients (64% vs 32%; advantage ratio of 3.61, 95% CI 2.59-5.04, p 0.0001)Risk factors reported in non-cancer patients, such as aging, IL-6, calcitonin injunclowandandandly elevated, and lymphocyte reduction, were validated in cancer patientsThe researchers also found that advanced cancer patients, tumor necrosis factor alpha, elevated N-end Pro-B brain sodium peptides, CD4-T cell reduction, and decreased albumin/globulin ratio were all risk factors for the severity of COVID-19 infection in cancer patientsCancer patients are more likely to become severely ill when infected with the new coronavirus than non-cancer patientsThe risk factors summarized in this study may contribute to early clinical monitoring of disease progression in patients with COVID-19 cancer